Home >> Therapeutic Area >> Law >> Food & Beverage >>

Rheumatoid Arthritis Therapeutics in Asia Pacific Markets to 2021 - Novel IL-6 and JAK Inhibitors to Stimulate Modest Growth Despite Brand Erosion of Blockbuster Anti-TNFs

Published: May-2015 | Format: PDF | GBI Research | Code: MRS - 18106


GBI Research, the leading business intelligence provider, has released its latest research: ‘Rheumatoid Arthritis Therapeutics in Asia Pacific Markets to 2021 - Novel IL-6 and JAK Inhibitors to Stimulate Growth In Spite of Brand Erosion of Blockbuster Anti-TNFs, which provides in-depth analysis of Rheumatoid Arthritis (RA) market within the Asia-Pacific (APAC) market covering the four countries of Australia, China, India and Japan. The report provides an estimation of market size for 2014, along with market forecast until 2021. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.

The value of the RA market in the APAC region amounted to an estimated $5.6 billion in 2014 and is expected to register a Compound Annual Growth Rate (CAGR) of 3.3% to reach $6.9 billion by 2021. The key drivers for growth in the APAC market include: the increasing prevalent population and the anticipated market launch of promising pipeline candidates. The late-stage pipeline which has a potential to stimulate growth during the forecast period include interleukin (IL)-6 inhibitors Sanofi/Regeneron’s sarilumab, Johnson & Johnson/GlaxoSmithKline’s [J&J/GSK’s] sirukumab, small molecules (four janus kinase [JAK] inhibitors: Eli Lilly/Incyte’s baricitinib, Loss of patent exclusitivity of major second-line biologic anti-TNF during such as Enbrel, Remicade and Humira by the end of the forecast period is the major barrier for growth in the RA market size in the APAC markets. Preference for less expensive alternatives to branded medicines, such as biosimilars and other alternate therapies is another major barrier in cost-conscious APAC markets, India and China.


  • The report analyzes treatment usage patterns, drug types available and pipeline and market forecasts for RA. It covers and includes:

  • A brief introduction to RA, including the disease’s pathophysiology, risk factors, diagnosis and an overview of pharmacotherapy and treatment algorithms.

  • In-depth analysis of the drug combinations used in the treatment of RA, including analyses of their safety, efficacy, and place in the disease treatment algorithm, as well as a heat map comparing the drug combinations in terms of safety and efficacy

  • A comprehensive review of the pipeline for OC therapies, including individual analysis of a number of late-stage pipeline drugs that have the potential to enter the market in the forecast period; the pipeline is analyzed on the basis of phase distribution, molecule type and molecular target, and route of administration

  • Additional in-depth analysis of pipeline drug clinical trials by phase, molecule type, trial size, and trial duration, and program failure rate analyses for each molecule type and mechanism of action

  • Multi-scenario forecast market data to 2021, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs, and the changes in disease epidemiology across the APAC markets

  • Discussion of the drivers and barriers for market growth

  • In-depth analysis of licensing and co-development deals involving drugs indicated in RA, including an outline of the key deals

Reasons To Buy

  • Primarily, the report will allow clients to gain a strong understanding of RA, helping to identify and clarify market opportunities and the competitive environment. It will also allow you to:

  • Understand the RA pipeline and the key trends in the current product development landscape

  • Observe detailed profiles for the promising pipeline products, including revenue forecasts, and gain an insight into how they are likely to compete in the market, and what their main competitors will be

  • Follow the trends in RA clinical trial size and duration in relation to industry averages and assess the potential risk of future developmental programs for RA therapeutics, depending on the mechanism of action, by considering the recorded clinical trial failure rates

  • Observe the potential growth patterns expected for the RA market over the forecast period, and identify which countries are expected to make the biggest contribution to this growth.

Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Disease Introduction
2.2 Symptoms
2.3 Etiology
2.4 Pathophysiology
2.5 Diagnosis
2.5.1 Physical Examination
2.5.2 Blood Tests
2.5.3 1987 Rheumatoid Arthritis Classification
2.5.4 2010 ACR-EULAR Classification Criteria for Rheumatoid Arthritis
2.6 Epidemiology
2.7 Co-morbidities and Complications
2.8 Disease Progression
2.9 Pharmacotherapy Algorithm
2.10 Treatment Options
2.10.1 Pharmacological
2.10.2 Methotrexate
2.10.3 Hydroxychloroquine
2.10.4 Leflunomide
2.10.5 Sulfasalazine
2.10.6 Cyclosporine
2.10.7 Prograf (tacrolimus)
2.10.8 Xeljanz (tofacitinib)
2.11 Other Non-biologics
2.11.1 Non-steroidal Anti-inflammatory Drugs
2.11.2 Painkillers
2.11.3 Glucocorticoids
2.12 Biologic Disease-Modifying Anti-rheumatic Drugs
2.12.1 Tumor Necrosis Factor Alpha Inhibitors
2.12.2 Interleukin Inhibitors
2.12.3 Other Biologics that Target B- and T-Cell Antigens
2.13 Disease Scoring Methods for Measuring Treatment Efficacy
2.13.1 Radiographic Progression
2.13.2 Clinical Disease Activity Index and Simplified Disease Activity Index
2.13.3 Disease Activity Score-28
2.13.4 American College of Rheumatology
2.13.5 Health Assessment Questionnaire

3 Marketed Products
3.1 Overview
3.2 Small-Molecule Disease-Modifying Anti-rheumatic Drugs
3.2.1 Methotrexate-Based Products
3.2.2 Xeljanz (tofacitinib) – Pfizer
3.3 Biologic Disease-Modifying Anti-rheumatic Drugs
3.3.1 Remicade (infliximab) – Johnson & Johnson, Merck
3.3.2 Humira (adalimumab) – AbbVie
3.3.3 Enbrel (etanercept) – Amgen, Pfizer and Takeda Pharmaceutical
3.3.4 Rituxan (rituximab) – Genentech, Biogen IDEC
3.3.5 Orencia (abatacept) – Bristol-Myers Squibb
3.3.6 Simponi (golimumab) – Johnson & Johnson, Merck
3.3.7 Cimzia (certolizumab pegol) – UCB
3.3.8 Kineret (anakinra) – Swedish Orphan Biovitrum
3.3.9 Actemra (tocilizumab) – Roche
3.3.10 Comparative Safety and Efficacy
3.4 Unmet Need

4 Product Pipeline
4.1 Overview
4.2 Pipeline Distribution by Phase of Development, Molecule Type, Route of Administration and Novelty
4.3 Pipeline Distribution by Mechanism of Action
4.3.1 Cytokine Inhibitors
4.3.2 B- and T-cells
4.3.3 Intracellular Kinases
4.4 Clinical Trial Analysis
4.4.1 Overall Attrition Rate
4.4.2 Attrition Rate by Phase, Molecule Type and Target
4.4.3 Average Clinical Trial Size by Molecule Type
4.4.4 Average Clinical Trial Size by Mechanism of Action
4.4.5 Average Clinical Trial Duration per Molecule Type by Product
4.4.6 Average Clinical Trial Duration per Mechanism of Action by Product
4.4.7 Primary and Secondary Endpoints
4.4.8 Summary
4.5 Promising Pipeline Drugs
4.5.1 Baricitinib – Eli Lilly
4.5.2 Sarilumab – Regeneron Pharmaceuticals/Sanofi
4.5.3 Sirukumab – Johnson & Johnson
4.5.4 Decernotinib – Vertex Pharmaceuticals
4.5.5 Masitinib
4.5.6 Denosumab
4.6 Comparative Heat Map

5 Market Forecasts
5.1 Asia-Pacific
5.1.1 Treatment Usage Patterns
5.1.2 Market Size
5.2 India
5.2.1 Treatment Usage Patterns
5.2.2 Annual Cost of Therapy
5.2.3 Market Size
5.3 China
5.3.1 Treatment Usage Patterns
5.3.2 Annual Cost of Therapy
5.3.3 Market Size
5.4 Australia
5.4.1 Treatment Usage Patterns
5.4.2 Annual Cost of Therapy
5.4.3 Market Size
5.5 Japan
5.5.1 Treatment Usage Patterns
5.5.2 Annual Cost of Therapy
5.5.3 Market Size
5.6 Drivers and Barriers of Rheumatoid Arthritis Therapeutics Market
5.6.1 Drivers
5.6.2 Barriers

6 Deals
6.1 Licensing Agreements
6.1.1 Deal Values by Therapeutic Molecule Type
6.1.2 Deal Values by Therapeutic Mechanism of Action
6.1.3 AstraZeneca Enters into Licensing Agreement with Rigel Pharma for Fostamatinib Disodium
6.1.4 Alder Biopharmaceuticals Enters into Licensing Deal with Bristol-Myers Squibb and Alder Biopharmaceuticals for Clazakizumab
6.1.5 Janssen Biotech Enters into a Licensing Deal with Astellas Pharma for Peficitinib
6.1.6 Ablynx Enters into a Licensing Deal with AbbVie for the Nanobody ALX-006
6.2 Co-development
6.2.1 Deal Values by Therapeutic Molecule Type and Phase
6.2.2 Deal Values by Therapeutic Mechanism of Action and Phase
6.2.3 GlaxoSmithKline enters into Global Agreement with Archemix
6.2.4 Abbott Laboratories Enters into Global Collaboration with Galapagos for filgotinib
6.2.5 Chroma Therapeutics Enters into a Co-development Agreement with GlaxoSmithKline

7 Appendix
7.1 All Pipeline Drugs by Phase of Development
7.1.1 Discovery
7.1.2 Preclinical
7.1.3 IND-CTA Filed
7.1.4 Phase I
7.1.5 Phase II
7.1.6 Phase III
7.2 Market Forecasts to 2021
7.3 Abbreviations
7.4 Bibliography
7.4.1 References for Figure 10
7.4.2 References for Figure 26
7.5 Research Methodology
7.5.1 Coverage
7.5.2 Secondary Research
7.5.3 Primary Research
7.5.4 Therapeutic Landscape
7.5.5 Geographical Landscape
7.5.6 Pipeline Analysis
7.6 Expert Panel Validation
7.7 Contact Us
7.8 Disclaimer

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)4995 View Pricing